Federal policy on compounded peptides just reached a pivotal milestone. On October 28, 2026, the Department of Health and Human Services (HHS) released an interim enforcement discretion policy governing the use of select peptide bulk drug substances in 503A compounding.
While headlines and industry chatter are already calling this an open green light for peptides, healthcare providers, compounding pharmacies, and medical spa directors must look past the buzz. HHS’s policy introduces a structured, conditional pause on enforcement, not a broad legalization. Understanding this shift requires a firm grasp of the nuances between federal discretion, statutory eligibility, and state-level regulation.
What Does HHS’s Interim Enforcement Policy Actually Do?
Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a bulk drug substance can generally only be compounded if it meets one of three criteria:
- It is the subject of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph.
- It is a component of an FDA-approved drug product.
- It appears on the statutory 503A bulk drug substances list established through federal rulemaking.
Because the peptides in question do not meet any of these criteria, they are not eligible for 503A compounding under the statute. From September 2023 until April 2026, FDA also placed them in “Category 2” of its interim bulks policy, which is reserved for substances FDA believes raise significant safety risks. FDA removed them from Category 2 in April 2026, but, as HHS itself acknowledges, neither the placement nor the removal changed their legal status under Section 503A.
The agency’s own experts were split. FDA’s Center for Drug Evaluation and Research (CDER) recommended against adding these peptides to the 503A bulks list, while FDA’s Pharmacy Compounding Advisory Committee voted in favor. HHS’s policy sides with the advisory committee, citing new manufacturing quality data and documented historical use.
Under HHS Secretary Robert F. Kennedy Jr.’s new directive, HHS has outlined an interim posture: until FDA decides, through final rulemaking, whether each peptide belongs on the 503A bulks list, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding specific peptides, provided every single condition established in the policy is strictly met. HHS has also reserved the right to revisit the policy, in whole or in part, if a safety signal or product quality issue emerges.
Crucial Clarification: Why Compounding These Peptides Isn’t Technically “Legal”
There is an enormous legal distinction between an affirmative authorization and an exercise of enforcement discretion.
- No Bulks List or Category 1 Placement: These peptides have not been added to the 503A bulks list, and the policy does not place them in FDA’s “Category 1” either. (Even Category 1 is itself only an enforcement policy, not a legal authorization.) Until a final rule adds a peptide to the bulks list, products compounded from it do not qualify for Section 503A’s exemptions from federal drug approval and labeling requirements.
- A Federal Enforcement Pause Only: The policy simply reflects an administrative commitment that HHS and the FDA will temporarily stand down on enforcement actions if compounders jump through explicit regulatory hoops. Because it is a policy rather than a regulation, HHS can revise or withdraw it without formal rulemaking.
- Narrow Scope: The policy covers only state-licensed pharmacies, federal facilities, and licensed physicians compounding under Section 503A. It does not extend to 503B outsourcing facilities, and it does nothing for “research use only” peptides, which HHS describes as a safety risk the policy is meant to discourage.
- State Pharmacy Boards Are Not Bound: This is the biggest blind spot for medical practices. A policy of federal enforcement discretion does not alter state law or compel state boards of pharmacy or medical boards to follow suit. Many states require compounding to comply with federal law or impose their own limits on bulk ingredients. In those states, compounding, prescribing, or dispensing these products may still be an actionable violation of state law, regardless of the federal position.
Assuming that federal enforcement discretion shields a practice from state licensing investigations or disciplinary action is a dangerous compliance mistake.
Which Peptides Are Covered?
The interim policy applies exclusively to six specific peptide bulk drug substances listed in Appendix A:
- BPC-157 (Acetate): subcutaneous, intramuscular, oral, or topical
- TB-500 (Acetate): subcutaneous or intramuscular injection
- Epitalon (Acetate): subcutaneous or intramuscular injection, dispensed in intermittent courses
- Semax (Free Base): intranasal only
- KPV (Acetate): oral or topical
- MOTS-c (Acetate): subcutaneous or intramuscular injection
The guidance specifies chemical identities, salt forms, and covered routes of administration for each substance. Compounding an alternate form or route not listed falls directly outside the scope of enforcement discretion.
Key Conditions Compounders Must Meet
Federal forbearance is entirely conditional. For a 503A pharmacy or physician to fall within the policy, it must meet ten stringent criteria, including:
- Registered Bulk Manufacturers & Stringent Characterization: The active pharmaceutical ingredient (API) must originate from a manufacturer registered with FDA under Section 510 of the FD&C Act and operating in compliance with current good manufacturing practice (CGMP). The API must be accompanied by a comprehensive Certificate of Analysis (COA) confirming identity, purity, potency, and the absence of endotoxins and contaminants.
- Single-API Formulations Only: The compounded product cannot be part of a multi-ingredient cocktail. It must contain only one active ingredient, the listed peptide, so that adverse events can be traced to a specific substance.
- Mandatory Reporting: Compounders must submit product reporting and report serious adverse events (whether or not considered drug-related) and product quality issues to FDA’s MedWatch program and to the states where the products are compounded and sent.
- Bioavailability Documentation: For oral formulations, compounders must maintain documented scientific evidence that their specific formulation achieves adequate bioavailability in humans.
- Required Labeling: The label must state, “This is a compounded drug product. Not for resale.”
- Standard 503A Prerequisites: The medication must be prescribed for an identified individual patient pursuant to a valid prescription and produced under sanitary conditions. Any delivery device packaged with or containing the drug must be an FDA 510(k)-cleared syringe.
What Should Medical Clinics and Wellness Providers Do Now?
While this interim guidance is a welcome shift for integrative and regenerative medicine, it introduces substantial compliance friction. Operating under enforcement discretion creates legal exposure that requires careful evaluation:
- Does your state pharmacy board align with federal enforcement discretion, or does state law maintain separate restrictions?
- Are the sourcing and COAs provided by your 503A pharmacy partners compliant with the strict analytical methods demanded by Appendix B?
- Does your clinical intake and prescription flow satisfy the single-API and individual-patient documentation standards?
- Is your practice prepared if HHS revises or withdraws the policy, or if your state takes a different position?
The interplay between federal compounding law, HHS and FDA policy, and state pharmacy and medical practice acts is complex. If your practice plans to prescribe, dispense, or administer compounded peptides under this interim framework, having compliant standard operating procedures and a sound legal strategy in place is critical.
Lengea Law advises med spas and aesthetic and wellness practices on peptide prescribing, compounding arrangements, and state regulatory compliance. If you have questions about how this policy applies to your practice or your state, contact our team to schedule a consultation.
This article is intended for general informational purposes only and does not constitute legal advice. Because the rules governing peptides and related services vary by state and continue to evolve, practices should consult qualified healthcare regulatory counsel regarding their specific operations.